Breaking News Instant updates and real-time market news.

RHHBY

Roche

$30.49

-0.05 (-0.16%)

16:55
10/09/16
10/09
16:55
10/09/16
16:55

Genentech reports Phase 3 data on Tecentriq in lung cancer

Genentech announced data from the pivotal Phase III OAK study of TECENTRIQ at the European Society of Medical Oncology 2016 Annual Meeting. The study showed TECENTRIQ helped people live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy. The OAK study evaluated people with non-small cell lung cancer whose disease had progressed on or after treatment with one or more platinum-based chemotherapy. The study enrolled people regardless of their programmed death-ligand 1 status and included both squamous and non-squamous disease types. Adverse events were consistent with those observed in previous TECENTRIQ studies.

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$30.49

-0.05 (-0.16%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

NVDA

Nvidia

08:38
09/26/17
09/26
08:38
09/26/17
08:38
Technical Analysis
Technical View: Nvidia bounces back from prior session losses »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$8.49

0.01 (0.12%)

08:38
09/26/17
09/26
08:38
09/26/17
08:38
Recommendations
Veracyte analyst commentary  »

Veracyte visibility…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

08:36
09/26/17
09/26
08:36
09/26/17
08:36
Hot Stocks
Darden says all businesses 'remain strong' »

Says to-go sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

TEUM

Pareteum

$1.06

0.01 (0.95%)

08:35
09/26/17
09/26
08:35
09/26/17
08:35
Hot Stocks
Breaking Hot Stocks news story on Pareteum »

Pareteum Corp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVEE

NV5 Global

$53.85

2.15 (4.16%)

08:34
09/26/17
09/26
08:34
09/26/17
08:34
Hot Stocks
NV5 Global awarded $14M program management contract by Merced County »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CSBR

Champions Oncology

$3.66

-0.09 (-2.40%)

08:33
09/26/17
09/26
08:33
09/26/17
08:33
Hot Stocks
Champions Oncology awarded $2M from National Cancer Institute »

Champions Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.96

0.03 (1.55%)

, UNIT

Uniti Group

$17.36

0.85 (5.15%)

08:33
09/26/17
09/26
08:33
09/26/17
08:33
Hot Stocks
Windstream says allegations in purported notice of default 'without merit' »

In a regulatory filing…

WIN

Windstream

$1.96

0.03 (1.55%)

UNIT

Uniti Group

$17.36

0.85 (5.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

OSIS

OSI Systems

$85.81

-1.08 (-1.24%)

08:32
09/26/17
09/26
08:32
09/26/17
08:32
Hot Stocks
OSI Systems receives $16M in orders for ETD systems »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Oct

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

08:32
09/26/17
09/26
08:32
09/26/17
08:32
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant says Mindset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GILD

Gilead

$83.61

0.34 (0.41%)

, KITE

Kite Pharma

$179.31

0.01 (0.01%)

08:31
09/26/17
09/26
08:31
09/26/17
08:31
Hot Stocks
Gilead, Kite Pharma announce expiration of HSR waiting period »

Gilead Sciences (GILD)…

GILD

Gilead

$83.61

0.34 (0.41%)

KITE

Kite Pharma

$179.31

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 12

    Feb

08:31
09/26/17
09/26
08:31
09/26/17
08:31
Conference/Events
Federal Reserve Bank of Atlanta President speaks on the economic outlook »

Atlanta Federal Reserve…

CAB

Cabela's

$61.50

0.03 (0.05%)

, SHOR

ShoreTel

08:30
09/26/17
09/26
08:30
09/26/17
08:30
Options
Two option delistings on September 26th »

Option delistings…

CAB

Cabela's

$61.50

0.03 (0.05%)

SHOR

ShoreTel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
09/26/17
09/26
08:30
09/26/17
08:30
General news
U.S. Case-Shiller home prices preview: »

U.S. Case-Shiller home…

MSFT

Microsoft

$73.26

-1.15 (-1.55%)

08:29
09/26/17
09/26
08:29
09/26/17
08:29
Recommendations
Microsoft analyst commentary  »

Valuing Microsoft should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 22

    Oct

08:29
09/26/17
09/26
08:29
09/26/17
08:29
Conference/Events
House Homeland Security Committee to hold a hearing »

The Oversight and…

SNX

Synnex

$116.50

0.4 (0.34%)

08:28
09/26/17
09/26
08:28
09/26/17
08:28
Recommendations
Synnex analyst commentary  »

Synnex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

08:28
09/26/17
09/26
08:28
09/26/17
08:28
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Subcommittee on…

RHT

Red Hat

$105.76

-0.54 (-0.51%)

08:28
09/26/17
09/26
08:28
09/26/17
08:28
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:27
09/26/17
09/26
08:27
09/26/17
08:27
Conference/Events
Senate Banking, Housing & Urban Affairs Committee to hold a hearing »

The Committee holds a…

08:26
09/26/17
09/26
08:26
09/26/17
08:26
Conference/Events
Federal Reserve Bank of Cleveland President attends annual meeting »

Cleveland Federal Reserve…

LLY

Eli Lilly

$84.64

0.73 (0.87%)

, MNTA

Momenta

$17.55

0.4 (2.33%)

08:25
09/26/17
09/26
08:25
09/26/17
08:25
Conference/Events
The Food & Drug Law Institute to hold a conference »

Advertising &…

LLY

Eli Lilly

$84.64

0.73 (0.87%)

MNTA

Momenta

$17.55

0.4 (2.33%)

PFE

Pfizer

$35.51

-0.45 (-1.25%)

ONCE

Spark Therapeutics

$87.00

1.85 (2.17%)

MDT

Medtronic

$78.27

-1.43 (-1.79%)

SNY

Sanofi

$49.97

-0.37 (-0.74%)

ALIOF

Actelion

JNJ

Johnson & Johnson

$131.17

-0.22 (-0.17%)

ACL

Alcon

VRTX

Vertex

$149.10

-2.16 (-1.43%)

MRK

Merck

$65.18

0.05 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 29

    Sep

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 27

    Oct

  • 31

    Oct

  • 08

    Nov

  • 30

    Nov

  • 12

    Jan

  • 02

    Feb

HNHPF

Hon Hai Precision

$6.93

-0.6165 (-8.17%)

08:25
09/26/17
09/26
08:25
09/26/17
08:25
Periodicals
Foxconn chairman to visit Wisconsin in October, DigiTimes reports »

Foxconn chairman Terry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$61.23

-0.36 (-0.58%)

08:24
09/26/17
09/26
08:24
09/26/17
08:24
Recommendations
Intercept analyst commentary  »

Intercept Ocaliva likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COR

CoreSite Realty

$108.57

0.08 (0.07%)

, CONE

CyrusOne

$58.80

-0.51 (-0.86%)

08:24
09/26/17
09/26
08:24
09/26/17
08:24
Conference/Events
RBC Capital to hold a tour »

Datacenter & Fiber…

COR

CoreSite Realty

$108.57

0.08 (0.07%)

CONE

CyrusOne

$58.80

-0.51 (-0.86%)

QTS

QTS Realty Trust

$51.45

-0.17 (-0.33%)

ZAYO

Zayo Group

$34.51

0.32 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

  • 13

    Nov

ICPT

Intercept

$61.23

-0.36 (-0.58%)

08:23
09/26/17
09/26
08:23
09/26/17
08:23
Recommendations
Intercept analyst commentary  »

Citi views Intercept…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.